← Leaderboards
Pan Zheng
Ohio State University
$7,391,253
Attributed
$12,368,942
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2009–22$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$12,368,942 · 9
By mechanism
R44$6,008,713 · 4
R01$5,361,755 · 4
RC1$998,474 · 1
Top collaborators
- Yang Liu8 shared
- Martin Devenport3 shared
- Kai He2 shared
- Tianhong Li2 shared
- Siwen Hu-Lieskovan1 shared
- Shyamasundaran Kottilil1 shared
- Christian Diego Rolfo1 shared
Most similar at Ohio State University
Same institution · by research overlap
- Yang Liu$21,443,530
- Jane Elizabeth Jackman$6,635,073
- D Joanne Lynn$242,494
- Xue-Feng Bai$4,770,529
- Hiranmoy Das$3,132,989
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularPatternResponseBaseImmune ResponseAffectTissuesSialic Acid Binding Ig-Like LectinDoseRegulationInjuryInflammationGeneticCellsAutoimmune DiseasesMouse ModelImmuneGenerationsInflammatoryPathway InteractionsMediatingMutationPathogenesisBiochemical Genetics
Grant awards (25)
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy$1,000,000
R44 · FY2022 · CA · contact PI
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy$1,000,000
R44 · FY2021 · CA · contact PI
SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients$1,000,000
R44 · FY2020 · CA · contact PI
A phase II dose expansion clinical trial testing the efficacy of CD24Fc for the prophylaxis of severe graft vs host disease and leukemia relapse$985,075
R44 · FY2020 · CA · contact PI
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy$400,000
R44 · FY2020 · CA · contact PI
Cindi Study: A Phase II Clinical Trial to Combine CD24Fc with Ipilimumab and Nivolumab to Decrease Immune Related Adverse Events (irAE)$396,664
R44 · FY2020 · CA · contact PI
A phase II dose expansion clinical trial testing the efficacy of CD24Fc for the prophylaxis of severe graft vs host disease and leukemia relapse$1,014,321
R44 · FY2019 · CA · contact PI
Checkpoints in the cellular response to tissue injury$427,019
R01 · FY2019 · AI
A Mouse Model to Assess Long Term Immunotherapy-related Adverse Effects in Children$404,265
R01 · FY2019 · CA · contact PI
A randomized, placebo-controlled, single-blinded clinical trial to assess safety and efficacy of CD24Fc in controlling cardiovascular disease risks of HIV-infected patients$212,653
R44 · FY2019 · HL · contact PI
A Mouse Model to Assess Long Term Immunotherapy-related Adverse Effects in Children$431,631
R01 · FY2018 · CA · contact PI
Checkpoints in the cellular response to tissue injury$427,019
R01 · FY2018 · AI
Checkpoints in the cellular response to tissue injury$475,387
R01 · FY2017 · AI
Checkpoints in the cellular response to tissue injury$475,387
R01 · FY2016 · AI
Checkpoints in the cellular response to tissue injury$475,387
R01 · FY2015 · AI
mTOR, Inflammation and Senescence of Hematopoietic Stem Cells$338,919
R01 · FY2014 · AG · contact PI
mTOR, Inflammation and Senescence of Hematopoietic Stem Cells$320,278
R01 · FY2013 · AG · contact PI
mTOR, Inflammation and Senescence of Hematopoietic Stem Cells$306,407
R01 · FY2012 · AG · contact PI
mTOR, Inflammation and Senescence of Hematopoietic Stem Cells$306,407
R01 · FY2011 · AG · contact PI
CD24 Polymorphism and Acetaminophen Toxicity$498,910
RC1 · FY2010 · GM · contact PI
mTOR, Inflammation and Senescence of Hematopoietic Stem Cells$317,067
R01 · FY2010 · AG · contact PI
CD24 Polymorphism and Acetaminophen Toxicity$499,564
RC1 · FY2009 · GM · contact PI
PROTO ONCOGENE PML AND TUMOR EVASION OF HOST IMMUNITY$225,361
R01 · FY2002 · CA
PROTO ONCOGENE PML AND TUMOR EVASION OF HOST IMMUNITY$218,797
R01 · FY2001 · CA
PROTO ONCOGENE PML AND TUMOR EVASION OF HOST IMMUNITY$212,424
R01 · FY2000 · CA